Equities
Health CareMedical Equipment and Services
  • Price (GBX)1,122.50
  • Today's Change-33.00 / -2.86%
  • Shares traded1.55m
  • 1 Year change+2.89%
  • Beta1.0191
Data delayed at least 20 minutes, as of Jul 11 2025 15:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.

  • Revenue in GBP (TTM)4.30bn
  • Net income in GBP305.21m
  • Incorporated1937
  • Employees17.35k
  • Location
    Smith & Nephew PLCBuilding 5, Croxley Park, Hatters LaneWATFORD WD18 8YEUnited KingdomGBR
  • Phone+44 207 401 7646
  • Fax+44 207 930 3353
  • Websitehttps://www.smith-nephew.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sectra AB160.17m43.65m5.08bn1.30k123.0836.2197.1431.712.932.9310.749.950.593527.851.401,595,180.0016.1715.7530.6429.9250.0460.2927.2522.411.72--0.043610.0919.854.4731.5118.877.19--
Ypsomed Holding AG696.37m81.37m5.29bn2.64k64.978.3634.007.596.416.4154.8649.790.61795.674.96283,232.207.225.5511.768.6739.0032.3211.699.240.687614.390.350619.7836.5413.6911.6649.4618.4861.54
ConvaTec Group PLC1.70bn141.12m5.38bn10.48k38.224.3017.643.170.06860.06860.82450.61040.63342.706.85161,770.405.273.356.173.9156.0755.738.325.880.86613.960.415793.606.854.6146.2081.0214.741.20
Demant A/S2.60bn335.47m6.54bn21.35k19.795.87--2.5113.3210.99103.2144.900.71181.995.901,050,120.009.188.8111.6013.1676.2374.7912.9012.321.226.070.61920.003.798.452.5214.610.1745--
Smith & Nephew plc4.30bn305.21m9.89bn17.35k32.392.5312.632.300.34850.34854.914.460.57130.73784.33248,086.204.053.624.984.4169.6470.477.097.101.336.420.386887.544.702.4956.65-7.24-1.36-2.01
BioMerieux SA3.45bn374.24m12.23bn14.75k32.783.3518.823.553.643.6433.5135.660.72171.815.23269,750.607.719.229.6611.9455.6656.5810.6812.351.2929.740.104420.248.318.2720.869.644.8836.49
Sonova Holding AG3.59bn502.61m12.86bn17.99k25.665.1917.393.589.049.0464.6644.700.65992.366.93214,863.809.3410.7412.1113.6672.4372.1614.1517.500.961818.800.351442.616.585.79-10.075.221.33--
Sartorius AG2.98bn82.69m12.87bn13.57k126.934.4925.624.311.391.3950.3139.250.33212.089.50254,590.501.516.192.008.6545.2749.694.5412.350.92592.830.546822.30-0.441713.10-59.14-11.7212.6915.84
Coloplast A/S3.23bn527.28m14.64bn16.74k29.757.9821.464.5420.1720.17123.3975.180.57142.455.921,710,716.009.3416.2113.1722.9167.5267.8516.3521.020.60828.870.588992.2310.338.545.625.4614.305.29
Data as of Jul 11 2025. Currency figures normalised to Smith & Nephew PLC's reporting currency: UK Pound GBX

Institutional shareholders

43.57%Per cent of shares held by top holders
HolderShares% Held
Cevian Capital ABas of 12 Jun 202574.47m8.50%
JPMorgan Chase Bank, NA (Investment Management)as of 01 Jul 202571.05m8.11%
UBS Asset Management (UK) Ltd.as of 01 Jul 202555.43m6.33%
Wellington Management Co. LLPas of 31 Dec 202042.67m4.87%
BlackRock Investment Management (UK) Ltd.as of 31 Mar 202532.06m3.66%
The Vanguard Group, Inc.as of 01 Jul 202531.19m3.56%
BlackRock Fund Advisorsas of 01 Jul 202522.27m2.54%
Norges Bank Investment Managementas of 25 Apr 202520.98m2.40%
MFS International (UK) Ltd.as of 01 Jul 202517.69m2.02%
Threadneedle Asset Management Ltd.as of 01 Jul 202513.88m1.58%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.